drugset

drugset / Trial / NCT04042740

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

NCT04042740 ↗

Phase 2 Completed 45 enrolled Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections AbbVie · collab National Institute of Allergy and Infectious Diseases (NIAID) · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks for treatment of acute hepatitis C (HCV), with or without HIV-1 coinfection.

Timeline

Start: 2019-11-20
Primary completion: 2023-05-18
Completion: 2023-08-22

Publications

Kim AY, Kang M, Umbleja T, Nunes EP, Marks KM, Luetkemeyer AF, Koebele C, Wimbish C, Fierer DS, Kliemann DA, Solomon SS, Kort J, Kiser JJ, Lauer GM, Chung RT, Sowah LA, Alston-Smith BL, Wyles DL, Naggie S; A5380 Study Team. Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C. Clin Infect Dis. 2026 Feb 4;81(6):1083-1090. doi: 10.1093/cid/ciaf305.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	glecaprevir	Other / unclassified	100 mg	Oral
Subject	pibrentasvir	Other / unclassified	40 mg	Oral

Indications